This article reviews our current understanding and modern treatment of multiple sclerosis (MS).
MS is a disabling condition resulting in devastating social and economic impacts. As MS …

Background Neurodegeneration is the pathological substrate that causes major disability in
secondary progressive multiple sclerosis. A synthesis of preclinical and clinical research …

Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating central nervous system
disorder that is more common in women, with onset often during reproductive years. The …

This study was undertaken to determine whether the production of melatonin, a hormone
regulating sleep in relation to the light/dark cycle, is altered in Huntington's disease. We …

Background and Objective To explore the relationship between slowly expanding lesions (SELs)
on MRI and disability in secondary progressive multiple sclerosis (SPMS). Methods We …

Introduction The major unmet need in multiple sclerosis (MS) is for neuroprotective therapies
that can slow (or ideally stop) the rate of disease progression. The UK MS Society Clinical …

Background: Cognitive impairment affects 50%–75% of people with secondary progressive
multiple sclerosis (PwSPMS). Improving our ability to predict cognitive decline may facilitate …

Introduction: Cognitive impairment in multiple sclerosis (MS) is increasingly being investigated
with resting-state functional MRI (rs-fMRI) functional connectivity (FC). However, results …

Secondary progressive multiple sclerosis (SPMS) is diagnosed retrospectively and involves
a clinical course characterized by a progressive accumulation of neurological disability, …

Background 1 H‐magnetic resonance spectroscopy ( 1 H‐MRS) may provide a direct index
for the testing of medicines for neuroprotection and drug mechanisms in multiple sclerosis (…